ArriVent BioPharma, Inc. Common Stock (AVBP) Stock

ArriVent BioPharma, Inc. Common Stock (AVBP) is a Healthcare stock trading at $31.73 (as of 2026-06-18), with a market capitalization of $1.39B and a trailing P/E of -9.0. Figures are sourced from first-party U.S. SEC EDGAR filings and market data.

ArriVent BioPharma, Inc. is a clinical-stage biopharmaceutical company focused on identifying, developing, and commercializing medicines for unmet needs in cancer patients. Its pipeline includes furmonertinib, an EGFR mutant-selective tyrosine kinase inhibitor in a phase 3 trial for NSCLC, and ARR-002, with work on targeted therapies for NSCLC and other solid tumors.

Valuation — source: SEC EDGAR (first-party)
Price$31.73
Market Cap$1.39B
P/E Ratio-9.0
Price / Book4.39
DCF Value (model)$-60.82
DCF Upside vs Price-291.6%
Profitability & Growth — source: SEC EDGAR
Return on Equity-44.8%
Current Ratio13.95
Valuation vs Sector & Industry
Stock P/E-9.0
Sector P/E (Healthcare)21.0
Industry P/E (Pharmaceutical Products)17.3
vs Sector-143.1%
vs Industry-152.3%
Smart-Money Activity — SEC Form 4 / 13F / Congressional disclosures
Top Institutional HolderSUVRETTA CAPITAL MANAGEMENT, LLC ($101.53M)
Institutional Holders Tracked10
Company
SectorHealthcare
IndustryPharmaceutical Products
CEOZhengbin Yao
Employees52
CountryUS
IPO Date2024-01-26

Related Companies (Business model: Biotech (Clinical / Commercial-Stage); 8 closest by market cap; US-domiciled)

  • Kura Oncology, Inc. (KURA)
  • Nektar Therapeutics (NKTR)
  • MoonLake Immunotherapeutics (MLTX)
  • Geron Corporation (GERN)
  • Janux Therapeutics, Inc. (JANX)
  • Alumis Inc. Common Stock (ALMS)
  • KalVista Pharmaceuticals, Inc. (KALV)
  • ORIC Pharmaceuticals, Inc. (ORIC)
AVBP earnings history · AVBP institutional & insider holders · Congress trades · Insider trades · Short interest · Stock screener

Data as of 2026-06-18.

Figures sourced from U.S. Securities and Exchange Commission (SEC EDGAR) filings and market data. Not personalized investment advice.